Samphire

Brain-based period pain and mood relief

London, UK

Samphire is developing the Nettle™ device for chronic menstrual conditions. The company was founded in 2021, has raised $7.3M in pre-seed and seed funding, and achieved CE certification for UK and EU markets.

Shareable draft

Check out Samphire on @MedStartr Today Samphire is developing the Nettle™ device for chronic menstrual conditions. The company was founded in 2021, has raised $7.3M in pre-seed and seed funding, and achieved CE certification for UK and EU markets. #ChronicMenstrualConditions #MedicalDevices #MedMo #MedStartrVentures

https://www.medstartr.ai/s/v0SCUTtjDPA

Note, this image was autogenerated by Syggy based on what we know about the company. It is not an official company publication.

Get Involved in Samphire

How We Help

Problem Statement

Chronic menstrual conditions affecting approximately 190 million people globally.

Core Technology

Nettle™ device

Key Differentiators

CE-certified medical device for UK and EU markets; Backed by decades of research

Clinical Focus

menstrual symptoms

Company Info

Business Model: Device Sales
Founded: 2021
Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now
Website: samphireneuro.com

Disease Areas

Chronic Menstrual Conditions

Technologies

Transcranial Direct Current Stimulation (tDCS)Brain StimulationCycle TrackingPersonalized InsightsApple Watch IntegrationFitbit IntegrationOura Ring IntegrationWearables & SensorsMobile Applications

Clinical & IP

🔬

Clinical Validation

Double-blind WIND 2024 trial: 72% pain reduction, 67% mood improvement, 100% PMDD symptom improvement in severe cases; Class IIa medical device (EU/UK)

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Samphire?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.